Compare AbCellera Biologics Inc (ABCL) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Expeditors International of Wshngtn Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Expeditors International of Wshngtn Inc trades at $164.43 (market cap $21.68B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 9.2× AbCellera Biologics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.98% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EXPD | |
|---|---|---|
Market Cap | $2.35B | $21.68B |
Sector | Health | Industrials |
52-Week High | $8.12 | $167.57 |
52-Week Low | $2.78 | $111.37 |
Enterprise Value | $1.99B | $20.93B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
EXPD trades at $165.74, down 1.09% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company shows consistent earnings beats, with Q1 2026 EPS of $1.71 surpassing expectations of $1.33. Revenue growth is steady, reaching $11.07B in 2025, while maintaining robust profitability with a net margin of 7.48% and ROE of 36.59%. Recent news highlights EXPD's resilience in transportation services amid industry challenges.
The stock presents a mixed outlook: strong fundamentals and technical momentum support upside potential, but valuation multiples like P/E of 26.77 suggest premium pricing. Risks include economic sensitivity and competitive pressures. Analyst consensus is cautious with 60.61% hold ratings, though price targets indicate limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
